MindWalk Targets a Blind Spot in AI Drug Discovery With HYFT, Flagging Hidden IP and Valuation Risks
MindWalk Holdings Corp. (NASDAQ: HYFT) says it has identified a growing and underappreciated risk facing pharmaceutical R&D: functional adjacency—situations where entirely different molecules deliver the same therapeutic effect, even when traditional sequence analysis suggests they are unrelated.
